Phaseline

Targets › KAT7

KAT7 (Histone acetyltransferase KAT7): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2029.

Catalytic subunit of histone acetyltransferase HBO1 complexes, which specifically mediate acetylation of histone H3 at 'Lys-14' (H3K14ac), thereby regulating various processes, such as gene transcription, protein ubiquitination, immune regulation, stem cell pluripotent and self-renewal maintenance and embryonic development. Some complexes also catalyze acetylation of histone H4 at 'Lys-5', 'Lys-8' and 'Lys-12'…. (UniProt, O95251)

Open in Phaseline: the race on KAT7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
IDEAYA BiosciencesIDE574
KAT6/KAT7 co-inhibitor
KAT6, KAT7Phase 1CancerDec 2029

Conditions

Cancer (1)

Modalities

small molecule (1)

Companies

IDEAYA Biosciences (1)

Related targets

KAT6 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.